An assessment of the tumor necrosis factor-alpha (TNF-α) receptor/nuclear factor-kappa B (TNFR/NF-κB) neuro-inflammatory pathway that measured NDEV biomarkers in plasma samples of infliximab-treated patients with BD revealed that the antidepressant response to infliximab, an antagonist of TNF-α, was modulated by changes in NDEV TNFR1 levels and showed an association between lower TNFR1 levels in NDEVs and higher overall cortical thickness [49]. Here, TNF is linked to Behcet disease.